Biophytis Leadership is Reinforced With New Chief Medical Officer Appointment
PARIS and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, today announces the appointment of Rob van Maanen MD MBA as Chief Medical Officer, member of the Executive Committee.
Stanislas Veillet, CEO of Biophytis, said: “I am very pleased to welcome Rob van Maanen to Biophytis. Rob brings with him extensive experience in drug development from both global pharma and biotech companies. He joins us at an important time for the Company after we recently announced encouraging results of Sarconeos (BIO101) in the COVID-19 and sarcopenia studies. Rob replaces Pr Jean Mariani who has held the CMO's responsibilities in the past 2 months transition period. I would like to thank Jean for taking on the role in the interim for us.”
Rob van Maanen is an MD graduate from the University of Utrecht (NL), holds an MBA from University of Amsterdam (NL), as well as medical licences in the UK and the Netherlands. He is an expert in global drug development, medical affairs, and pharmacovigilance with more than 20 years of experience in both large pharmaceutical companies and small biotechs. With large pharma companies, his past roles include Senior Medical Director with Astellas, but also numerous clinical management and pharmacovigilance positions for Roche, Novartis, Eisai and Organon, where he has led multiple studies through both FDA and EMA requirements. With the Biotech sector, just before joining Biophytis, Rob was holding the CMO position for Khondrion, a dutch clinical-stage company discovering and developing therapies targeting orphan inherited mitochondrial diseases.
Rob van Maanen, CMO of Biophytis, said: "I'm very excited to be joining Biophytis at a cucial time where the Company is making strong progress in its clinical programs, and with its leading product Sarconeos (BIO101) potentially reaching the market in a short time frame. I look forward to working on Biophytis' next strategic milestones."
Investor Relations contact
IDEA SHOWCASE RECEPTION AND PITCH EVENT - Open to all Badge Holders
The Compelling Case for LiDAR
Who Benefits from Network Slicing?